These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway. Wang J; Ling X; Zhou M; Ding G; Peng B; Wan J Neoplasma; 2021 May; 68(3):535-545. PubMed ID: 33724860 [TBL] [Abstract][Full Text] [Related]
4. EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47. Hu LY; Zhuang WT; Chen MJ; Liao J; Wu DF; Zhang YX; Pang LL; Huang YH; Mao TQ; Yang MJ; Peng PJ; Liang JX; Chen L; Zeng LJ; Zhang L; Fang WF J Thorac Oncol; 2024 Aug; 19(8):1186-1200. PubMed ID: 38553005 [TBL] [Abstract][Full Text] [Related]
5. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013 [TBL] [Abstract][Full Text] [Related]
6. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC. Nigro A; Ricciardi L; Salvato I; Sabbatino F; Vitale M; Crescenzi MA; Montico B; Triggiani M; Pepe S; Stellato C; Casolaro V; Dal Col J Front Immunol; 2019; 10():3135. PubMed ID: 32082304 [TBL] [Abstract][Full Text] [Related]
7. Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells. Tang ZH; Su MX; Guo X; Jiang XM; Jia L; Chen X; Lu JJ Anticancer Agents Med Chem; 2018; 18(4):550-555. PubMed ID: 28730963 [TBL] [Abstract][Full Text] [Related]
8. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells. Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301 [TBL] [Abstract][Full Text] [Related]
9. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression. Jiang Y; Zhuo X; Wu Y; Fu X; Mao C Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119144. PubMed ID: 34599981 [TBL] [Abstract][Full Text] [Related]
10. Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Tang ZH; Cao WX; Su MX; Chen X; Lu JJ Toxicol Appl Pharmacol; 2017 Apr; 321():18-26. PubMed ID: 28237877 [TBL] [Abstract][Full Text] [Related]
11. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735 [TBL] [Abstract][Full Text] [Related]
12. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Tang ZH; Lu JJ Cancer Lett; 2018 Apr; 420():242-246. PubMed ID: 29425688 [TBL] [Abstract][Full Text] [Related]
13. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310 [TBL] [Abstract][Full Text] [Related]
14. Discovery of highly potent and selective EGFR Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818 [TBL] [Abstract][Full Text] [Related]
15. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK; Wei W; Sun SY Mol Cancer Res; 2021 Oct; 19(10):1622-1634. PubMed ID: 34183449 [TBL] [Abstract][Full Text] [Related]
16. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. Zhang X; Wang Y; Fan J; Chen W; Luan J; Mei X; Wang S; Li Y; Ye L; Li S; Tian W; Yin K; Ju D J Immunother Cancer; 2019 Dec; 7(1):346. PubMed ID: 31829270 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. Zhou P; Chen G; Gao M; Wu J Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506 [TBL] [Abstract][Full Text] [Related]
19. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670 [TBL] [Abstract][Full Text] [Related]
20. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]